CEL-SCI Files to Sell 1M Shares of Common Stock for Holders

TipRanks17:20 ET

CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A...

BenzingaOct 22 09:26 ET

CEL-SCI Announces Potential Impact on Multikine Following FDA ODAC Meeting

TipRanksOct 22 09:25 ET

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

BusinesswireOct 22 09:15 ET

CEL-SCI Selects Ergomed as CRO as It Gears Up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer

BusinesswireOct 1 06:00 ET

CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to Be in the Treatment Group for Surgery and Radiation

BusinesswireSep 16 07:30 ET